FCM - Instituto de Genética Experimental

URI permanente para esta comunidad

https://rephip.unr.edu.ar/handle/2133/1908

Examinar

Examinando FCM - Instituto de Genética Experimental por Materia "Apoptosis"

Mostrando 1 - 2 de 2
  • Miniatura
    ÍtemAcceso Abierto
    De la inmunovigilancia al escape tumoral: Historia de un enemigo con múltiples estrategias de resistencia y contra-ataque
    (Sociedad Española de Inmunología, 2006-04) Scharovsky, O. Graciela; Matar, Pablo; Zacarías Fluck, Mariano; Rico, María José; Rabinovich, Gabriel A.
    Tumors must circumvent the immune response of the host to become clinically detectable. For this purpose, malignant cells have devised multiple strategies to thwart immune attack. These mechanisms are suggested to conspire in advanced stages of cancer to limit the ability of the immune system to restrain the tumor and the effectiveness of immunotherapy strategies to successfully eradicate malignant cells. From tumor biology to cancer immunotherapy and back again, we will summarize here some of the most important mechanisms used by tumors to evade the immune response and their potential impact in the design of cancer immunotherapy strategies.
  • Miniatura
    ÍtemAcceso Abierto
    Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models
    (Spandidos (Grecia), 2008-05) Rozados, Viviana R.; Hinrichsen, Lucila Isabel; Binda, María Mercedes; Gervasoni, Silvia I.; Matar, Pablo; Bonfil, Daniel R.; Scharovsky, O. Graciela
    Despite its effectiveness as an antineoplastic drug, doxorubicin (DOX) is usually associated with cardiotoxicity. Lovastatin (LOV), a hypolipidemic agent used in the clinic, has been demonstrated to have antitumoral and antimetastatic effects in murine models. Since the two agents arrest tumor cells in different phases of the cell cycle and induce apoptosis, the goal of this study was to examine the efficacy of a combination therapy with LOV and low doses of DOX, in an attempt to obtain an improved antitumoral effect devoid of toxicity, by using a rat B-cell lymphoma and a mouse mammary tumor. In the two models, the combined treatment showed a synergistic antitumoral effect, which is mainly ascribed to an increased apoptotic response elicited by a LOV/DOX combination than either agent alone. The therapeutic benefit demonstrated by the combination treatment is further emphasized by the lack of toxicity.